Triumvira Submits Investigational New Drug (IND) Application to the FDA and Clinical Trial Application (CTA) to Health Canada to Evaluate TAC01-CD19\, a T Cell Antigen Coupler Therapy\, in Ph 1/2 TACTIC-19 Trial